These results also suggest that the simultaneous use of substances that affect different TFIIH functions is an interesting alternative to treat cancer and opens the possibility of searching for new drugs that may affect other TFIIH subunits, particularly if we consider the hepatotoxic effect of TPL and its derivatives [55]. The gene discussed is ERCC2; the disease is cancer.